Each stakeholder (employers, patients, family members, physicians, payers) values the impact of novel therapies differently, said Thomas Graf, MD, chief medical officer and vice president, Horizon Blue Cross Blue Shield of New Jersey.
Each stakeholder (employers, patients, family members, physicians, payers) values the impact of novel therapies differently, said Thomas Graf, MD, chief medical officer and vice president, Horizon Blue Cross Blue Shield of New Jersey.
Transcript
How does the impact of novel therapies vary between different stakeholders?
This is really interesting. For patients, it’s wonderful. We have treatments that are revolutionary, that can cure or dramatically improve the survival outcomes for diseases that really had no good options. The challenges though, they come with significant side effects. For some of them, you actually have to be hospitalized in the intensive care unit when you’re given the drug. That gives you some idea the danger associated with it. Even a successful therapy is a little bit challenging. From a payer perspective or provider perspective, understanding that risk to the patients and the members, understanding that impact of the cost, is a real challenge.
The other piece that I think most people haven’t really thought about is as we think about value in healthcare. Each stakeholder values it differently: employers, patients, family members, physicians, payers. But the biggest challenge is the time horizon that each of those recognize their value. For patients, the time horizon is obviously their life, they're open to measurement on and ongoing fashion. For employers, perhaps the time horizon that’s relevant is the time someone’s an employee. So, amortizing that half a million-dollar dose drug across the employed time makes a little more sense. Theoretically, as an insurance company, you’d value someone just for the time that they’re an insured member, which is a real challenge in these situations, because they need the treatment now, it’s gonna be very expensive now. In a year or two, as you start to break even on that member, of course you wouldn’t with these new therapies but conceptually, they may very well be insured somewhere else, so figuring out how to get that cost fare across the system, it is a real challenge. There’s no good answers yet.
Need for Pharmacogenomic Testing in Mental Health Care Explored at AMCP 2024
April 17th 2024Presenters from Mayo Clinic discussed the benefits of implementing pharmacogenomic testing in mental health care for the betterment of patient outcomes, reducing medical costs, and more at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
CMS Leaders Describe Their Partnership to Align Programs, Address ACOs’ Concerns
April 11th 2024As CMS’ suite of value-based and accountable care models evolves, leaders from across the agency detailed how they are working together to streamline quality reporting and encourage the move to a population health mindset while addressing providers’ concerns.
Read More